Other Events ·
HUTCHMED to host expert webcast on savolitinib Phase III data in NSCLC
HCMHUTCHMED (China) Ltd
HUTCHMED (China) Limited announced a virtual webcast scheduled for November 5, 2026, co-hosted with Citigroup Global Markets Asia Limited. The event will feature Professor Yi-Long Wu and Dr. Weiguo Su to discuss recent Phase III clinical data for savolitinib in MET-driven non-small cell lung cancer presented at the ESMO Congress 2026. Savolitinib is a selective MET inhibitor marketed in China, jointly developed with AstraZeneca. HUTCHMED (China) Limited is an innovative biopharmaceutical company focused on targeted therapies and immunotherapies for cancer.